Jonathan Schwach

Dr. Jonathan Schwach is a researcher affiliated with Ludwig Maximilian University of Munich (LMU), specifically within the BioSysM department. He is a core member of the Leonhardt Group, which focuses on interdisciplinary biomedical research. His work integrates molecular biology, immunology, and biophysics to advance therapeutic strategies and imaging technologies.

While specific educational details are not provided in the text, his research contributions suggest a strong background in biomedical sciences or related disciplines. Dr. Schwach’s research interests prominently feature antibody engineering, cancer therapy, and epigenetic mechanisms. He explores antibody-drug conjugates for targeted cancer treatment and investigates chromatin organization’s role in cellular regulation, reflecting a blend of clinical and fundamental research.

His publications highlight trends in developing next-generation antibody-based therapies, particularly against leukemia stem cells, and advancing microscopy techniques for reversible staining. Collaborations span across disciplines, including with groups like CALM and the Technical Staff, indicating a team-oriented approach to biomedical innovation.

Dr. Schwach’s work contributes to the broader goals of the Leonhardt Group and affiliated initiatives, though specific grants or advising roles are not explicitly detailed here.